TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
9.12
+0.05 (0.55%)
Aug 15, 2025, 1:30 PM CST
-37.32%
Market Cap 6.55B
Revenue (ttm) 151.47M
Net Income (ttm) -55.07M
Shares Out 717.84M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 854,420
Average Volume 1,039,669
Open 9.10
Previous Close 9.07
Day's Range 9.08 - 9.30
52-Week Range 7.44 - 15.15
Beta 0.16
RSI 62.24
Earnings Date Aug 22, 2025

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.